Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
- None.
- None.
Insights
The announcement by Annovis Bio regarding the completion of data cleaning for their phase II/III study of buntanetap signifies a pivotal moment in their clinical development pathway. The promptness in transitioning from data cleaning to analysis is indicative of operational efficiency, which can be a positive signal to investors about the company's ability to manage its clinical trials. The focus on a neurodegenerative disease like Alzheimer's, which has a high unmet medical need, suggests potential for significant market impact if the drug proves to be effective.
From an investment perspective, the anticipation of topline efficacy data in the near term is a critical event that could influence the company's stock volatility. Positive results could lead to a surge in stock price due to the large market for Alzheimer's therapies. However, it's essential to note that the path to FDA approval is long and uncertain, even with positive phase II/III results, as further studies and regulatory hurdles remain.
The Alzheimer's treatment market is a multi-billion dollar industry with a growing patient population, which makes the development of new therapies by companies like Annovis Bio particularly significant. The fact that buntanetap is being tested in three different dosages highlights the company's strategy to optimize therapeutic efficacy and safety, which could differentiate it from existing treatments if successful.
Investors should consider the competitive landscape and the commercial potential of buntanetap. The success of this drug could position Annovis Bio as a key player in the neurodegenerative disease space, potentially attracting partnership opportunities or even acquisition interest from larger pharmaceutical companies. On the flip side, should the study results not meet expectations, there could be a negative impact on the company's valuation and future funding prospects.
The methodology of the phase II/III study, being a randomized, double-blind, placebo-controlled trial, aligns with the gold standard for clinical research, which increases the credibility of the results. The dose-ranging aspect of the study is important for determining not only the efficacy but also the optimal dosing required to balance benefits with potential side effects.
It's important for stakeholders to understand that the number of patients who completed the study versus those who were enrolled can affect the statistical power and conclusiveness of the study. The fact that over 90% of enrolled patients completed the study is a strong indicator of the trial's robustness. Nevertheless, the real test will be the topline data and its subsequent peer-reviewed publication, which will be scrutinized for both efficacy and safety outcomes.
MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its phase II/III study of buntanetap in patients with mild to moderate Alzheimer’s disease (AD). Topline efficacy data is expected in April.
"We are excited to share that we now move from data cleaning to organization and statistical evaluation of data for our Alzheimer’s study, which was completed in February. To clean data this fast is truly a tremendous achievement,” said Cheng Fang, Ph.D., Senior Vice President of Annovis. “The team has been working hard to provide trustworthy data, and we look forward to the topline results as we plan to announce it next month.”
The phase II/III AD study was a randomized, double-blind, placebo-controlled trial investigating the efficacy, safety, and tolerability of buntanetap in patients with mild to moderate AD. This was a dose ranging study where patients received either one of three doses of buntanetap - 7.5mg, 15mg, or 30mg - or placebo on top of their standard of care for 12 weeks. Over 700 patients were screened with a total of 353 patients enrolled and 327 patients completed the study.
“We are grateful to the participants who enrolled and completed the study as well as their caregivers and families for supporting their loved one’s involvement in this trial; we truly couldn’t do it without them. We’d also like to thank our study partners whose teamwork and dedication allowed us to complete the study in a timely fashion,” said Melissa Gaines, Senior Vice President, Clinical Operations.
About Buntanetap
Buntanetap (formerly known as Posiphen or ANVS401) attacks neurodegeneration by inhibiting the formation of multiple neurotoxic proteins - amyloid beta, tau, alpha synuclein, and TDP43 - thereby improving synaptic transmission, axonal transport and neuroinflammation. Dysregulation of these pathways has been shown to be the cause of nerve cell degeneration and ultimately death. By attacking these pathways, buntanetap has the ability to reverse neurodegeneration in Alzheimer’s disease.
About Annovis Bio, Inc.
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and other chronic neurodegenerative diseases. It is believed to be the only company developing a drug for both AD and PD designed to inhibit more than one neurotoxic protein to restore axonal and synaptic activity. By improving brain function, the company’s goal is to treat memory loss and dementia associated with AD as well as body and brain dysfunction associated with PD. For more information on Annovis Bio, please visit the Company's website www.annovisbio.com and follow us on LinkedIn and Twitter.
Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The Company advises caution in reliance on forward-looking statements. Forward-looking statements include, without limitation, the Company's plans related to clinical trials. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those implied by forward-looking statements, including regarding patient enrollment, the effectiveness of Buntanetap and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety and tolerability of buntanetap. See also additional risk factors set forth in the Company's periodic filings with the SEC, including, but not limited to, those risks and uncertainties listed in the section entitled "Risk Factors," in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC. All forward-looking statements in this press release are based on information available to the Company as of the date of this filing. The Company expressly disclaims any obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Investor Contacts:
Maria Maccecchini, Ph.D.
maccecchini@annovisbio.com
FAQ
What is the phase of the study conducted by Annovis Bio, Inc. (ANVS)?
When is the topline efficacy data expected to be announced?
How many patients were screened for the study?
How many patients completed the study?
What were the doses of buntanetap used in the study?
